Table 4 Subgroup analysis of the PSM cohort (n = 220)
| Â | number of patients | Overall survival | Disease-free survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
5-year OS % (95% CI) | HR(95% CI) | p value* | 5-year DFS % (95% CI) | HR(95% CI) | p value* | ||||
S-1 | XELOX | S-1 | XELOX | ||||||
Sex | |||||||||
 Male | 152 | 73 (63–84) | 78 (68–90) | 0.63 (0.32–1.27) | 0.196 | 66 (56–78) | 77 (67–88) | 0.60 (0.32–1.14) | 0.117 |
 Female | 68 | 71 (57–89) | 76 (59–97) | 0.93 (0.35–2.48) | 0.890 | 64 (49–83) | 68 (49–94) | 0.75 (0.32–1.77) | 0.507 |
Age (years) | |||||||||
  < 65 | 138 | 78 (68–88) | 87 (79–96) | 0.66 (0.29–1.50) | 0.316 | 71 (61–83) | 77 (67–90) | 0.73 (0.36–1.44) | 0.361 |
  ≥ 65 | 82 | 62 (48–80) | 64 (48–85) | 0.69 (0.32–1.51) | 0.358 | 56 (42–74) | 69 (55–87) | 0.55 (0.261–1.18) | 0.125 |
Stage (AJCC 7th) | |||||||||
 IIA | 7 | 100 (100–100) | 100 (100–100) | NA | NA | 100 (100–100) | 100 (100–100) | NA | NA |
 IIB | 40 | 89 (64–97) | 92 (57–99) | 0.67 (0.06–7.48) | 0.747 | 85 (61–95) | 92 (54–99) | 0.38(0.04–3.68) | 0.405 |
 IIIA | 54 | 89 (70–96) | 75 (33–93) | 1.56 (0.31–7.96) | 0.593 | 85 (66–94) | 77 (53–90) | 1.58(0.43–5.76) | 0.487 |
 IIIB | 67 | 78 (65–94) | 72 (55–94) | 1.35 (0.50–3.69) | 0.554 | 66 (51–85) | 74 (60–92) | 0.84 (0.34–2.04) | 0.697 |
 IIIC | 52 | 27 (10–46) | 68 (51–90) | 0.32 (0.14–0.76) | 0.009 | 22 (8–41) | 57 (39–84) | 0.32 (0.15–0.70) | 0.004 |
 All II | 47 | 90 (78–100) | 94 (83–100) | 0.58 (0.05–6.40) | 0.655 | 87(74–100) | 93 (82–100) | 0.35 (0.04–3.34) | 0.360 |
 All III | 173 | 67 (58–78) | 73 (62–86) | 0.73 (0.40–1.31) | 0.285 | 60 (50–71) | 69 (59–81) | 0.67 (0.40–1.13) | 0.133 |
N stage | |||||||||
 N0 | 18 | 100 (100–100) | 100 (100–100) | NA | NA | 100 (100–100) | 100 (100–100) | NA | NA |
 N1 | 33 | 93 (59–99) | 81 (52–94) | 3.40 (0.35–32.86) | 0.290 | 87 (56–96) | 80 (50–93) | 1.81(0.30–10.96) | 0.519 |
 N2 | 75 | 86 (71–94) | 77 (42–92) | 1.40 (0.36–5.41) | 0.623 | 82 (65–91) | 78 (57–90) | 1.18(0.42–3.34) | 0.757 |
 N3 | 94 | 47 (34–65) | 71 (58–86) | 0.45 (0.23–0.87) | 0.019 | 38 (26–55) | 66 (52–82) | 0.40 (0.21–0.75) | 0.004 |
T stage | |||||||||
 T1 | 7 | 100 (100–100) | 100 (100–100) | NA | NA | 75 (13–96) | 100 (100–100) | 0.42(0.00–41.43) | 0.712 |
 T2 | 16 | 86 (33–98) | 86 (33–98) | 0.87 (0.05–13.85) | 0.919 | 88 (39–98) | 86 (33–98) | 0.93(0.06–14.83) | 0.957 |
 T3 | 80 | 80 (68–93) | 81 (66–99) | 0.75 (0.25–2.23) | 0.604 | 74 (62–90) | 80 (67–95) | 0.78 (0.30–2.05) | 0.617 |
 T4a,b | 117 | 64 (52–78) | 72 (59–88) | 0.69 (0.35–1.37) | 0.290 | 56 (42–68) | 67 (50–79) | 0.61 (0.33–1.14) | 0.121 |
LNR group | |||||||||
 LNR 0 | 18 | 100 (100–100) | 100 (100–100) | NA | NA | 100 (100–100) | 100 (100–100) | NA | NA |
 LNR 1 | 71 | 94 (78–98) | 86 (61–96) | 3.01 (0.55–16.59) | 0.205 | 88 (72–95) | 85 (65–94) | 1.43(0.41–4.99) | 0.579 |
 LNR 2 | 80 | 74 (57–85) | 72 (50–86) | 0.84 (0.34–2.10) | 0.705 | 66 (49–79) | 74 (56–85) | 0.73(0.32–1.68) | 0.464 |
 LNR 3 | 51 | 26 (12–55) | 67 (50–89) | 0.28 (0.11–0.71) | 0.020 | 20 (9–47) | 54 (35–82) | 0.29 (0.13–0.65) | 0.004 |